Lung Cancer:

€ 281,99
Lieferbar innerhalb von 2-3 Tagen
April 2012



Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them.


Molecular pathology of lung cancer: Alejandro Corvalan and Ignacio Wistuba

Tumor microenvironment: Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, Steven Dubinett

Racial and ethnic diversity in lung cancer: Carol J. Etzel, Sumesh Kachroo

Pharmacogenetics of lung cancer: Xifeng Wu, Jian Gu

Lung cancer prevention Nir Peled, Robert L. Kieth, Fred Hirsch

Adjuvant and neoadjuvant therapy of non-small cell lung cancer: Katherine Pisters

Chemoradiotherapy for inoperable non-small cell lung cancer: James Cox and David J. Stewart

Management of advanced non-small cell lung cancer- front line treatment: William N. William Jr. and David J. Stewart

Chemotherapy in previously-treated patients with non-small cell lung cancer: Frank V. Fossella

Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer: Paul Wheatley-Price and Frances A, Shepherd

Angiogenesis inhibitors in lung cancer : Leora Horn and Alan Sandler

Other molecular targeted agents in non-small cell lung cancer: Benjamin Besse and Jean Charles Soria

Vaccine therapy for lung cancer: John Nemunaitis and Jack Roth

Gene-based therapies for lung cancer: John Nemunaitis and Jack Roth

Lung cancer resistance to chemotherapy: David J. Stewart

Small cell carcinoma: Emer Hanrahan and Bonnie Glisson

Mesothelioma: Mary Frances McAleer, Reza J. Mehran, and Anne Tsao

Advances in oncology clinical research statistical and study design methodologies: B. Nebiyou Bekele

Palliativecare for patients with lung cancer: David Hui and Eduardo Bruera

The future of lung cancer: Sophie Sun, Joan H. Schiller, Monica Spinola, John Minna



From the reviews: "This comprehensive review of prevention and treatment strategies for malignancies of the thorax thoroughly investigates tumor biology and discusses established and emerging therapies. ... The book is written for a wide audience that includes pathologists, pulmonologists, medical oncologists, radiation oncologists, and surgical oncologists. ... I would highly recommend this book to anyone interested in current and future therapies for lung cancer. This is one of the most comprehensive and up-to-date accounts of the field." (Nagendra S. Koneru, Doody's Review Service, July, 2010)
EAN: 9781617796845
ISBN: 1617796840
Untertitel: Prevention, Management, and Emerging Therapies. 2010. Auflage. Previously published in hardcover. Sprache: Englisch.
Verlag: Humana Press
Erscheinungsdatum: April 2012
Seitenanzahl: 556 Seiten
Format: kartoniert
Es gibt zu diesem Artikel noch keine Bewertungen.Kundenbewertung schreiben